FDA Reviewing Potential Treatment for Levodopa-Induced Dyskinesia
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
The designation has been granted to potentially treat neuropathic pain associated with diabetic peripheral neuropathy.
The treatment is currently being investigated in a Phase 2 trial in adults with Angelman syndrome
The FDA has accepted an NDA for Arymo ER (morphine sulfate; Egalet) extended-release tablets.
Translarna (ataluren) is for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
The FDA has granted Orphan Drug designation to IONIS-HTT (Ionis) for the treatment of Huntington’s disease.